PDCD1 and cancer: For example, in the treatment of metastatic melanoma, patients are treated with the PD-1 inhibitor pembrolizumab alongside the targeted therapy vemurafenib, which inhibits the BRAF oncogene.462,463 The results showed that this combination led to significant cancer regression and resulted in the downregulation of exhaustion markers on circulating T cells.